Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US10822343B2
公开(公告)日:2020-11-03
The present invention provides thiazole compounds of Formula I
wherein W, Y,
R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
本发明提供了式 I 的噻唑化合物
其中 W, Y、
R0、R2、R4、R5、R6、R7、X1、X2、X3 和 X4 如本文所定义,或其立体异构体、同系物、药学上可接受的盐、原药酯或溶 剂形式,其中所有变量如本文所定义。这些化合物是血小板聚集抑制剂,因此可用作治疗或预防血栓栓塞性疾病的药物。